Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Atreca stock (BCEL)

Buy Atreca stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Atreca is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the PINK and all prices are listed in US Dollars. Atreca employs 90 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Atreca stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Atreca stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BCEL. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Atreca stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Atreca stock price (PINK: BCEL)

Use our graph to track the performance of BCEL stocks over time.

Atreca shares at a glance

Information last updated 2024-07-21.
Latest market close$0.09
52-week range$0.05 - $1.12
50-day moving average $0.09
200-day moving average $0.20
Wall St. target price$2.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.50

Atreca price performance over time

Historical closes compared with the close of $0.09 from 2024-06-14

1 week (2024-07-12) N/A
1 month (2024-06-19) N/A
3 months (2024-04-23) 12.50%
6 months (2024-01-23) -59.28%
1 year (2023-07-21) -91.96%
2 years (2022-07-22) -95.59%
3 years (2021-07-23) 7.06
5 years (2019-07-23) 15.69

Atreca financials

Gross profit TTM $0
Return on assets TTM -51.2%
Return on equity TTM -182.7%
Profit margin 0%
Book value $0.27
Market Capitalization $3.6 million

TTM: trailing 12 months

Atreca share dividends

We're not expecting Atreca to pay a dividend over the next 12 months.

Have Atreca's shares ever split?

Atreca's shares were split on a 1:6 basis on 6 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atreca shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Atreca shares which in turn could have impacted Atreca's share price.

Atreca share price volatility

Over the last 12 months, Atreca's shares have ranged in value from as little as $0.052 up to $1.12. A popular way to gauge a stock's volatility is its "beta".

BCEL.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Atreca's is 1.026. This would suggest that Atreca's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Atreca overview

Atreca, Inc. , a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.

Frequently asked questions

null
What percentage of Atreca is owned by insiders or institutions?
Currently 2.682% of Atreca shares are held by insiders and 8.385% by institutions.
How many people work for Atreca?
Latest data suggests 90 work at Atreca.
When does the fiscal year end for Atreca?
Atreca's fiscal year ends in December.
Where is Atreca based?
Atreca's address is: 835 Industrial Road, South San Francisco, CA, United States, 94070
What is Atreca's ISIN number?
Atreca's international securities identification number is: US04965G1094
What is Atreca's CUSIP number?
Atreca's Committee on Uniform Securities Identification Procedures number is: 04965G109

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site